Observational studyRadiology. Cardiothoracic imaging2024
Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity.
Erratum issuedOpen access · greenAbstract readObservational Study
In one paragraph
Observational study in Radiology. Cardiothoracic imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 13 citations in OpenAlex.
- What about the heart - pediatric ALL survivors show cardiopulmonary limitations in the MinimALL Study.European journal of pediatrics · 2025Trial
- Article
- Association of left ventricular end-systolic volume with peri-echocardiographic acute kidney injury proxy beyond ejection fraction: a retrospective linked echocardiographic cohort study.BMC cardiovascular disorders · 2026Article
- Calculation of Ejection Fraction Using Cardiac Computed Tomography: Clinical Evolution, Reliability, and Technological Challenges-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- "Critical reflections on mid-range ejection fraction and outcomes in STEMI patients".Heart and vessels · 2026Article
- Refining Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction.JACC. CardioOncology · 2026Article
- Response to letter by Dr. Mumtaz: critical reflections on mid-range ejection fraction and outcomes in STEMI patsients.Heart and vessels · 2026Article
- Pediatric Cardiac Imaging With Second- and Third-generation Dual Source CT Scanners: Radiation Dose, and Diagnostic Accuracy in Comparison With Echocardiography and MRI-A Systematic Review and Meta-analysis.Journal of the Saudi Heart Association · 2026Review
- Cardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy.Pediatric radiology · 2025Review
- Myocardial Strain Measurements Obtained with Fast-Strain-Encoded Cardiac Magnetic Resonance for the Risk Prediction and Early Detection of Chemotherapy-Related Cardiotoxicity Compared to Left Ventricular Ejection Fraction.Diagnostics (Basel, Switzerland) · 2025Article
- Cardio-Oncology and Multi-Imaging Modalities.Journal of clinical medicine · 2025Review
- Use of Ultrasound Contrast Agents in Stress Echocardiography: Three for the Price of One.CASE (Philadelphia, Pa.) · 2025Article
- Outcomes and Left Ventricular Ejection Fraction in Cardiac Magnetic Resonance: Challenging the "Higher Is Better".Journal of the American Heart Association · 2025Article
- Development and validation of a predictive model for cancer therapy-related cardiac dysfunction in breast cancer patients using echocardiographic indicators.American journal of cancer research · 2025Article
- Multimodal assessment of the left ventricular ejection fraction by echocardiography, cardiac computed tomography and cardiac magnetic resonance in patients after SARS-CoV2 infection.Frontiers in physiology · 2025Article
- Machine learning models using multimodal data accurately predict chemotherapy-induced cardiotoxicity in breast cancer.Frontiers in cardiovascular medicine · 2025Article
- Cardiac Magnetic Resonance and Cardiac Implantable Electronic Devices: Are They Truly Still "Enemies"?Medicina (Kaunas, Lithuania) · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 1 institution in 2 countries.
Muhummad Sohaib NazirFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0003-2749-1033
Joseph OkaforFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0002-1021-6134
Theodore MurphyFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).
Maria Sol AndresFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0002-9554-2026
Sivatharshini RamalinghamFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0009-0009-2582-9548
Stuart D RosenFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0001-8034-0037
Amedeo ChiribiriFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0003-3394-4289
Sven PleinFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0002-0997-4384
Sanjay PrasadFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).
Raad MohiaddinFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0002-1768-7457
Dudley J PennellFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0001-5523-1314
A John BaksiFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).ORCID 0000-0001-5492-1743
Rajdeep KhattarFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).
Alexander R LyonFrom the Cardio-Oncology Service (M.S.N., T.M., M.S.A., S.R., S.D.R., A.R.L.), Department of Echocardiography (J.O., R.K.), and Cardiovascular Magnetic Resonance Unit (S. Prasad, R.M., D.J.P., A.J.B.), Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, Guy's and St Thomas' Hospital, London SE1 7EU, United Kingdom (M.S.N., A.C., S. Plein); and National Heart & Lung Institute, Imperial College London, London, United Kingdom (S.D.R., S. Prasad, R.M., D.J.P., A.J.B., A.R.L.).
Royal Society · GB
Funding
British Heart Foundation CH/16/2/32089British Heart Foundation RG/19/1/34160
Abstract
Purpose To compare left ventricular ejection fraction (LVEF) measured with echocardiography and cardiac MRI in individuals with cancer and suspected cardiotoxicity and assess the potential effect on downstream clinical decision-making. Materials and Methods In this prospective, single-center observational cohort study, participants underwent same-day two-dimensional (2D) echocardiography and cardiac MRI between 2011 and 2021. Participants with suboptimal image quality were excluded. A subset of 74 participants also underwent three-dimensional (3D) echocardiography. The agreement of LVEF derived from each modality was assessed using Bland-Altman analysis and at relevant thresholds for cardiotoxicity. Results A total of 745 participants (mean age, 60 years ± 5 [SD]; 460 [61.7%] female participants) underwent same-day echocardiography and cardiac MRI. According to Bland-Altman analysis, the mean bias was -3.7% ± 7.6 (95% limits of agreement [LOA]: -18.5% to 11.1%) for 2D echocardiography versus cardiac MRI. In 74 participants who underwent cardiac MRI, 3D echocardiography, and 2D echocardiography, the mean LVEFs were 60.0% ± 10.4, 58.4% ± 9.4, and 57.2% ± 8.9, respectively (
Indexed as
NeoplasmsVentricular Function, LeftCardiotoxicityEchocardiographyFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesStroke VolumeCardiacEchocardiographyMR Functional Imaging
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.